



Short profile

PixCell Medical

CHARITÉ/BIH-PARTNER WANTED!
More information [here](#)

| | |
|-------------------------|---|
| Medical field | Oncology, Pathology (and other) |
| Product (name and type) | HemoScreen, Diagnosis |
| Growth stage | Transition to Scale, FDA cleared, CE-marked |
| Founders | Avishay Bransky, Ph.D. (CEO), Prof. Max Herzberg (Chairman), Hanan Ben-Asher (COO, BD Manager), Yaara Ben-Yosef, Ph.D (Director of RA and Clinical Affairs) |

Description of product:

HemoScreen is a Point-Of-Care Testing (POCT) Complete Blood Count (CBC) analyzer. It is miniature, portable and provides the results within 5 minutes. It includes a reader and disposable cartridges. A drop of blood, acquired from a finger stick or tube, is applied to the cartridge and the cartridge is inserted into the reader. The operation is exceptionally simple and the instrument requires no maintenance or calibration making it ideal for use outside conventional lab settings. Furthermore, as the method is based on AI analysis of cells images, abnormal cells can be quantified.

Project goal:

Prove impact on health economics, workflow and clinical benefits. Evaluate utility in primary care as early screening for blood cancers.

Project type:

Collaboration with leading medical institutions to validate the clinical utility of the new technology and its impact on workflow, clinical outcome, and patient satisfaction. PixCell searches for a partner that can help to define and optimize the product specifications through a "real-life" scenario, which will allow improving healthcare services to patients. Estimated Project Duration: 12 months.



Eligible by the IIA



dotan@pixcell-medical.com



+972-4-959-3516 / 7



www.pixcell-medical.com/hemoscreen

